WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ:ACUS) announced that Rajeev A. Jain, Ph.D., Manager of Formulations Support and Pharmaceutics for Acusphere, presented a poster on the “Preparation of an Emulsion Formulation of Clopidogrel for Intravenous Administration” at the 34th Annual Meeting & Exposition of the Controlled Release Society. Dr. Jain’s poster focused on an intravenous formulation of clopidogrel bisulfate, developed by Acusphere using its proprietary technology. Clopidogrel is the active ingredient in Plavix®, an anti-platelet drug marketed by Bristol Myers Squibb that generated over $3 billion in worldwide revenue in 2006. Plavix is available in oral dosage form, and there is no currently approved formulation for intravenous delivery, limiting its utility in the hospital setting. This poster is available on the Acusphere corporate web site at www.acusphere.com.
